Tesaro Scores Biggest 2011 VC Round with $101M Series B

In the largest Series B financing of the year  and what appears to be the largest biotech venture financing for any round in 2011  privately held oncology start-up Tesaro Inc. raised $101 million to advance lead candidate rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting, and a small-molecule inhibitor of anaplastic lymphoma kinase.